Braveheart Bio Director Bos Jasper Receives Stock Option Award

What Happened

• Bos Jasper, a director of Braveheart Bio, was granted a derivative award equal to 30,000 shares on 2026-08-05. The Form 4 reports the transaction as an "A" (award/grant) for 30,000 shares at $0.00 (derivative), and the award will vest in full by the earlier of August 5, 2027 or the issuer's next annual meeting, subject to continued service.

Key Details

• Transaction date: 2026-08-05; reported price: $0.00 (derivative award, Form 4)
• Securities acquired: 30,000 (derivative / stock option award)
• Shares owned after transaction: not specified in the filing
• Footnote: the shares underlying the stock option vest in full upon the earlier of (i) Aug 5, 2027 or (ii) the issuer's next annual meeting, subject to continued service (per F1)
• Transaction code: A = Award/Grant; Filing date: 2026-08-07 (timely — within Form 4 reporting window)

Context

• This was a stock option award (derivative), not an immediate purchase of common shares. The options must vest before the director can exercise them (exercise would typically require payment of any exercise price and could create a taxable event).
• Director awards are common as compensation and do not, by themselves, indicate a buy or sell signal. This filing is informational and was submitted on time.